In our continuing coverage of the Biotechnology sector this week, analyst Liisa Bayko shares her thoughts on the market for products that help with female sexual dysfunction: 

• Close to 40% of women are afflicted with some degree of sexual dysfunction.
• As yet, there is no product on the market for female sexual dysfunction.
• Proctor & Gamble (PG) have had their product for female sexual Dysfunction, Intrinsia, approved in Europe. This same product was denied by the FDA.
• It remains to be seen whether or not the FDA feels that the female sexual dysfunction is something that needs to be treated pharmacologically, or if it is something they deem more in the psychosocial realm.
• To the Ms. Bayko, and the people at Next Generation Equity Research, are excited by this area, but warn investors that it is high risk/high reward.

For the full interview with Ms. Bayko, click here.

This entry was posted on Wednesday, September 26th, 2007 at 4:51 pm and is filed under Healthcare Stocks. You can follow any responses to this entry through the RSS 2.0 feed.